Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
When ambition meets ambiguity: The trends and sentiments shaping biotech in 2026
Deepali Suri, President ICON Biotech, provides insights into what biotech leaders anticipate in the coming two years, the therapies and modalities they’re focused on now and what macro and micro factors are impacting their operations.
-
China biotech continues its growth trajectory
Yao Zhong, vice president general manager for ICON China Mainland and Hong Kong, discusses latest survey results on the Chinese biotech market.
-
2025 in Review: Global biotech and funding trends
In this interview, Deepali Suri, President of ICON Biotech, breaks down the key trends shaping today’s biotech industry and their global impact. Using insights from ICON’s global and China biotech surveys, capturing input from more than 260 biotech leaders worldwide, Suri highlights emerging therapeutic innovations, the growing influence of AI in R&D, and how geopolitical tensions are redefining international drug development strategies.
-
The formula for biotech success in 2026: Confidence, resilience and funding
For biotech companies the past two years have been challenging. In 2025 ICON Biotech conducted a follow-up survey of biotech leaders, previously carried out in 2023. The new results show changing trends in the risks, challenges and opportunities in the biotech sector.
-
Enabling Innovation: How China-based biotechs are shaping global drug development
Yao Zhong, ICON China Mainland and Hong Kong, is sharing some of the findings from the 2025 China biotech sector survey report. Read more on how a strategic partnership fuels global ambition.
-
Next-generation modalities, precision trials, and AI-driven breakthroughs in oncology
The panelists discussed promising scientific and strategic pathways in oncology, including next-generation therapeutic modalities, precision trial strategies, AI applications with demonstrated and measurable impact, regulatory and market readiness, and collaborative models for accelerating early-phase oncology programs.
-
Bring In The Biotechs: ICON’s new biotech President, Deepali Suri, shares her vision for 2026 and beyond
When Deepali Suri stepped into her new role as president of ICON’s biotech division in September 2025, she brought with her more than two decades of experience across big pharma, biotech, and CROs. She also brought a clear vision for the industry’s future. Read to learn more.
-
Research paints China as ‘global innovation powerhouse’
ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.
-
China becoming dominant force in biotech sector, survey says
Chinese biotech dominance and opportunities for Western companies to stay competitive have been highlighted in surveys released by clinical research organization ICON.
-
Accelerating timelines and reducing cost in early clinical drug development
Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to simplify complexity and speed timelines. This article discusses how the integration of science, technology and strategic insight can transform challenges into opportunities for breakthrough success.
